<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of kidney disease in patients with cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of kidney disease in patients with cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of kidney disease in patients with cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mitchell H Rosner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark A Perazella, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Colm C Magee, MD, MPH, FRCPI</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary C Curhan, MD, ScD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3287911832"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cancer is the second leading cause of death in the United States and is associated with significant morbidity [<a href="#rid1">1</a>]. As survival rates of patients with cancer have improved over the past few decades, an increasing number of cancer survivors have or will develop kidney disease associated with malignancy or its treatment. A variety of kidney complications can occur among patients with cancer, including acute kidney injury (AKI), chronic kidney disease (CKD), proteinuria and nephrotic syndrome, and electrolyte disorders.</p><p>This topic will provide an overview of the major kidney complications that affect patients with cancer. Kidney disease in patients with multiple myeloma or other monoclonal gammopathies, kidney disease among patients with cancer who have undergone hematopoietic cell transplantation (HCT), and the nephrotoxicity of specific chemotherapeutic agents are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7211.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/109635.html" rel="external">"Diagnosis and treatment of monoclonal gammopathy of renal significance"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7197.html" rel="external">"Kidney disease following hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2834.html" rel="external">"Nephrotoxicity of chemotherapy and other cytotoxic agents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy"</a>.)</p><p></p><p class="headingAnchor" id="H918749173"><span class="h1">EPIDEMIOLOGY AND PROGNOSIS</span></p><p class="headingAnchor" id="H3008631732"><span class="h2">AKI in patients with cancer</span><span class="headingEndMark"> — </span>Acute kidney injury (AKI) is a common complication in patients with cancer and is associated with reduced treatment dose intensity, lower remission rates, shorter duration of disease control, and increased mortality, hospital length of stay, and cost [<a href="#rid2">2-6</a>]. The incidence of AKI in patients with cancer is likely higher than the incidence observed in patients without cancer.</p><p>Overall risk has been addressed in the following observational studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a Danish population-based study that followed 37,267 patients with incident cancer from 1999 to 2006, the one- and five-year risks of AKI, as defined by a &gt;50 percent increase in serum creatinine compared with a baseline serum creatinine measured within one year of cancer diagnosis, were 17.5 and 27 percent, respectively [<a href="#rid7">7</a>]. The risk of AKI was highest in patients with kidney cancer (44 percent), liver cancer (33 percent), and multiple myeloma (32 percent). Kidney replacement therapy (KRT) was required in 5.1 percent of patients within one year of AKI onset.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 163,071 patients undergoing systemic treatment of cancer in Ontario, Canada between 2007 and 2014, nearly 1 in 10 patients experienced a hospitalization or received dialysis for AKI [<a href="#rid8">8</a>]. Notably, the annual incidence of AKI increased from 18 to 52 per 1000 person-years over the study period. Malignancies with the highest five-year incidence of AKI were multiple myeloma (26 percent), bladder cancer (19 percent), leukemia (15 percent), and kidney cancer (14 percent). Advanced cancer stage, chronic kidney disease (CKD), and diabetes were all associated with an increased risk of AKI, and AKI risk was accentuated during the 90-day period following systemic therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 9828 children in China hospitalized with cancer from 2013 to 2015, 17 percent experienced AKI, including 6 percent with community-acquired AKI and 11 percent with hospital-acquired AKI [<a href="#rid6">6</a>]. The cancers with the highest incidence of AKI were urinary tract cancer (26 percent), liver cancer (19 percent), and retroperitoneal malignancies (19 percent). In-hospital mortality was higher among children with AKI compared with those without AKI (5.4 versus 0.9 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In other studies, the risk of AKI was higher in patients with cancer who were critically ill [<a href="#rid9">9,10</a>], those receiving treatment for a high-risk myelodysplastic syndrome or acute leukemia [<a href="#rid11">11</a>], recipients of hematopoietic cell transplantation (HCT), and those who had undergone nephrectomy for renal cell carcinoma (RCC) [<a href="#rid12">12,13</a>]. (See  <a class="medical medical_review" href="/d/html/7197.html" rel="external">"Kidney disease following hematopoietic cell transplantation"</a> and <a class="local">'AKI after nephrectomy'</a> below.)</p><p></p><p>Most observational studies have shown that patients with cancer who develop AKI, particularly those who require KRT, have a higher risk of mortality than those who do not have AKI [<a href="#rid4">4,6,9,11,14-17</a>]. In one study of 288 patients with cancer admitted to a cancer intensive care unit in Brazil, mortality among patients with RIFLE Risk, Injury, and Failure stages of AKI was 49, 62, and 87 percent, respectively, compared with 14 percent among those without AKI [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/7238.html" rel="external">"Definition and staging criteria of acute kidney injury in adults"</a>.)</p><p>Overall severity of illness, age, and functional status are likely to contribute to the prognosis in these patients, and the presence of cancer should not be considered an absolute exclusion criterion for KRT.</p><p class="headingAnchor" id="H265816610"><span class="h2">CKD in patients with cancer</span><span class="headingEndMark"> — </span>Chronic kidney disease (CKD) is also a common complication of cancer and its therapy. This may be related in part to the high prevalence of preexisting CKD in patients with various types of malignancy. Two large observational studies, each involving nearly 5000 patients with cancer, found that approximately 50 percent of patients with an active malignancy had an estimated glomerular filtration rate (eGFR) of &lt;90 mL/min/1.73 m<sup>2</sup> [<a href="#rid18">18,19</a>]. The prevalence of stage 3 and 4 CKD among these patients was 12 and less than 1 percent, respectively. In a prospective study of 4077 patients with various cancers, 30 percent had an eGFR of 45 to 59 mL/min/1.73 m<sup>2</sup>, and 8.3 percent had an eGFR of &lt;45 mL/min/1.73 m<sup>2</sup> [<a href="#rid20">20</a>]. Similar rates of CKD have been reported in other large observational studies of patients with cancer [<a href="#rid21">21,22</a>]. (See  <a class="medical medical_review" href="/d/html/16406.html" rel="external">"Definition and staging of chronic kidney disease in adults"</a>.)</p><p>Having cancer appears to increase the risk of kidney failure needing kidney replacement therapy (KRT; hemodialysis or peritoneal dialysis, or kidney transplantation). In a Korean population-based cohort study that compared 824,365 patients newly diagnosed with cancer with 1,648,730 patients without cancer who were matched for age, sex, eGFR, hypertension, and diabetes, having cancer was associated with an increased risk of kidney failure requiring KRT after adjusting for multiple variables (adjusted hazard ratio [HR] 2.29, 95% CI 2.20-2.39) [<a href="#rid23">23</a>]. Multiple myeloma was associated with the highest risk of kidney failure requiring KRT (adjusted HR 18.97, 95% CI 14.31-25.15) compared with other cancer types, followed by leukemia, lymphoma, kidney cancer, ovarian cancer, and liver cancer. The contribution of chemotherapy administration, and the specific cytotoxic agents used, was not addressed. </p><p>Adult survivors of childhood cancer are also at risk for long-term CKD and albuminuria. In a Dutch nationwide cross-sectional cohort study of 1024 adult childhood cancer survivors who had undergone nephrectomy, abdominal radiotherapy, total body irradiation (TBI), <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, or hematopoietic cell transplantation five or more years prior to study entry, at a median age of 32 (range 27 to 37) approximately 4 percent had an eGFR of &lt;60 mL/min/1.73 m<sup>2</sup>, compared with none of age- and sex-matched controls [<a href="#rid24">24</a>]. Albuminuria (defined as a urine albumin-to-creatinine ratio &gt;3 mg/mmol [26.6 mg/g]) was present in 16 percent of survivors compared with 1 percent of controls. Risk factors for CKD included nephrectomy (odds ratio [OR] 3.7), abdominal radiotherapy (OR 1.8), prior ifosfamide (OR 2.9), and cumulative cisplatin dose &gt;500 mg/m<sup>2</sup> (OR 7.2); risk factors for albuminuria included TBI (OR 2.3), abdominal radiotherapy dose &gt;30 Gy (OR 2.6), and prior ifosfamide (OR 1.6).</p><p>Patients with cancer and CKD may have an increased risk of death compared with those without CKD. However, the risk may vary by cancer type, and some studies have found no differences in mortality between patients with cancer with and without CKD [<a href="#rid20">20-22,25</a>].</p><p>The relationship between CKD and cancer appears to be reciprocal since both CKD and end-stage kidney disease (ESKD) appear to be risk factors for the development of a number of malignancies. A retrospective study of more than 1 million adults assessed the association between severity of kidney disease and the risk of incident cancer [<a href="#rid26">26</a>]. Lower eGFR was associated with an increased risk of kidney cancer (adjusted HR 2.3, 95% confidence interval [CI] 1.8-2.9 for an eGFR of &lt;30 mL/min/1.73 m<sup>2</sup>) and urothelial cancer but not other cancers. Patients with ESKD on dialysis have an increased risk for kidney parenchymal cancer that is related to the development of acquired kidney cystic disease, which increases with time on dialysis [<a href="#rid27">27,28</a>]. (See  <a class="medical medical_review" href="/d/html/1946.html" rel="external">"Cancer screening in patients on maintenance dialysis"</a> and  <a class="medical medical_review" href="/d/html/1683.html" rel="external">"Acquired cystic disease of the kidney in adults", section on 'Renal cell carcinoma'</a>.)</p><p class="headingAnchor" id="H1733811074"><span class="h1">ASSESSMENT OF KIDNEY FUNCTION IN PATIENTS WITH CANCER</span><span class="headingEndMark"> — </span>Patients with cancer require frequent assessment of kidney function to ensure proper dosing of chemotherapeutic agents and to monitor ongoing therapies for evidence of nephrotoxicity. There is no consensus on the optimal formula to estimate glomerular filtration rate (GFR) in patients with cancer. The preferred formula is the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, which is also the preferred formula among patients without cancer. However, other measures of kidney function such as the Cockcroft-Gault equation for creatinine clearance are still sometimes used in calculating dose adjustments for chemotherapeutic agents. Measurement of GFR (real-time GFR assessment) would be the optimal method to assess GFR in patients with cancer and would allow more accurate drug dosing in this population, especially in those with kidney function impairment. However, this method is complex, time consuming, and cumbersome to do in clinical practice. (See  <a class="medical medical_review" href="/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p>Several classes of anticancer drugs may increase serum creatinine concentrations by impairing tubular secretion of creatinine [<a href="#rid29">29</a>]. These drugs, which can be associated with an erroneously reduced eGFR, include the following:  </p><p class="bulletIndent1"><span class="glyph">●</span>Cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poly-adenosine diphosphate ribose polymerase (PARP) inhibitors</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Certain tyrosine kinase inhibitors (such as anaplastic lymphoma kinase [ALK] inhibitors, BCR-ABL inhibitors, epidermal growth factor receptor [EGFR] inhibitors, and human epidermal growth factor receptor 2 [HER2] inhibitors)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mesenchymal-epithelial transition (MET) inhibitors</p><p></p><p class="headingAnchor" id="H3294309251"><span class="h1">ACUTE KIDNEY INJURY IN PATIENTS WITH CANCER</span><span class="headingEndMark"> — </span>Acute kidney injury (AKI) is a common complication among patients with cancer [<a href="#rid2">2,3,7</a>]. The etiologies of AKI in patients with cancer include all those that occur in the general population as well as certain etiologies that are specific to this patient group  (<a class="graphic graphic_table graphicRef112218" href="/d/graphic/112218.html" rel="external">table 1</a>). These etiologies can be categorized into prerenal, intrinsic renal, and postrenal causes based upon the location of the lesion. However, in many cases, the cause of AKI in patients with cancer is multifactorial.</p><p>The evaluation of the patient with AKI is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/102834.html" rel="external">"Evaluation of acute kidney injury among hospitalized adult patients"</a>.)</p><p class="headingAnchor" id="H355850586"><span class="h2">Prerenal causes</span><span class="headingEndMark"> — </span>The most frequent cause of AKI in patients with cancer is prerenal disease, which often results from volume depletion (as a consequence of chemotherapy-related nausea, vomiting, or diarrhea) and/or the use of medications such as diuretics  (<a class="graphic graphic_table graphicRef112218" href="/d/graphic/112218.html" rel="external">table 1</a>) [<a href="#rid30">30-32</a>]. Hypercalcemia or the use of medications that affect renal autoregulation, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or nonsteroidal antiinflammatory drugs, can further exacerbate the risk and severity of prerenal AKI [<a href="#rid30">30-32</a>]. Given the risks of kidney dysfunction, the risk-to-benefit ratio of using any of these agents should be carefully considered in patients with advanced malignancy as well as those who are at high risk of volume depletion during chemotherapy.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7216.html" rel="external">"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury in adults", section on 'Causes of prerenal disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7230.html" rel="external">"NSAIDs: Acute kidney injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers", section on 'Reduction in GFR'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/832.html" rel="external">"Clinical manifestations of hypercalcemia", section on 'Kidney'</a>.)</p><p></p><p>Among patients who have undergone myeloablative allogeneic hematopoietic cell transplantation (HCT), a hepatorenal-like syndrome secondary to sinusoidal obstruction syndrome (veno-occlusive disease) can occur. (See  <a class="medical medical_review" href="/d/html/7197.html" rel="external">"Kidney disease following hematopoietic cell transplantation", section on 'Transplant-specific causes'</a> and  <a class="medical medical_review" href="/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults"</a>.)</p><p class="headingAnchor" id="H4089164987"><span class="h2">Intrinsic renal causes</span><span class="headingEndMark"> — </span>There are multiple intrinsic renal causes of AKI among patients with cancer  (<a class="graphic graphic_table graphicRef112218" href="/d/graphic/112218.html" rel="external">table 1</a>). Etiologies that are specific to patients with cancer are discussed below. (See  <a class="medical medical_review" href="/d/html/102834.html" rel="external">"Evaluation of acute kidney injury among hospitalized adult patients", section on 'Major causes and classification of AKI'</a>.)</p><p class="headingAnchor" id="H1618805571"><span class="h3">Light chain cast nephropathy (formerly called myeloma kidney)</span><span class="headingEndMark"> — </span>Light chain cast nephropathy refers to acute or chronic kidney disease (CKD) that results from the overproduction and filtration of toxic light chains, leading to both tubular injury and intratubular cast formation and obstruction. Light chain cast nephropathy is a common cause of AKI among patients with multiple myeloma and is the most common histologic lesion in kidney biopsies of patients with monoclonal gammopathy. It has been rarely reported in patients with other monoclonal gammopathies such as Waldenström macroglobulinemia, lymphoma, and chronic lymphocytic leukemia (CLL).</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation", section on 'Light chain cast nephropathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7211.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Treatment and prognosis", section on 'Light chain cast nephropathy (myeloma kidney)'</a>.)</p><p></p><p class="headingAnchor" id="H2956896844"><span class="h3">Tumor lysis syndrome</span><span class="headingEndMark"> — </span>Tumor lysis syndrome (TLS), considered an oncologic emergency, is caused by massive tumor cell lysis, which releases large amounts of intracellular contents into the systemic circulation, resulting in hyperkalemia, hyperuricemia, hyperphosphatemia, and hypocalcemia. AKI due to TLS results from the formation of crystals composed of uric acid, calcium phosphate, and/or xanthine, which can cause intratubular obstruction, inflammation, and a reduction in glomerular filtration rate (GFR). TLS most often occurs after initiation of chemotherapy in patients with high-grade lymphomas (such as Burkitt lymphoma) or leukemias, although it may develop spontaneously or with treatment of other cancers that have a high proliferative rate or large tumor burden.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/17050.html" rel="external">"Tumor lysis syndrome: Prevention and treatment"</a>.)</p><p></p><p class="headingAnchor" id="H2312513174"><span class="h3">Tumor infiltration</span><span class="headingEndMark"> — </span>Metastases to the kidney are not uncommon. However, involvement that is severe enough to impair kidney function requires that both kidneys are involved and occurs mainly with rapidly growing hematologic malignancies, such as lymphoma or acute leukemia [<a href="#rid33">33-35</a>]. Among patients with lymphoma, kidney parenchymal infiltration has been reported in up to 60 percent of cases [<a href="#rid36">36-38</a>]; however, most of these cases are undiagnosed [<a href="#rid37">37</a>]. Parenchymal infiltration is usually subclinical, although patients may present with AKI, proteinuria and/or hematuria, and bilaterally enlarged kidneys on imaging. The diagnosis is established by kidney biopsy, although this is not always required. The mechanism by which kidney parenchymal infiltration causes AKI is unclear but may involve compression of the renal tubules and microvasculature, leading to tubular obstruction and ischemia. Successful treatment of the primary malignancy with chemotherapy may result in an improvement in kidney function.</p><p>Plasma cell infiltration of the kidney can occur in patients with multiple myeloma, but this only rarely causes AKI [<a href="#rid36">36,39,40</a>]. (See  <a class="medical medical_review" href="/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation", section on 'Less common causes of AKI'</a>.)</p><p class="headingAnchor" id="H2270651476"><span class="h3">Thrombotic microangiopathy</span><span class="headingEndMark"> — </span>Thrombotic microangiopathy (TMA) is a well-described complication of cancer and its therapy [<a href="#rid41">41-43</a>]. TMA may be associated with the primary cancer or, more likely, with therapeutic regimens such as <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> or vascular endothelial growth factor (VEGF) inhibitors (such as <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>) [<a href="#rid43">43</a>]. TMA associated with VEGF inhibitors has a better prognosis after stopping the causative agent than do other forms of drug-induced TMA [<a href="#rid44">44</a>]. TMA may also occur in the setting of HCT, where it is often associated with calcineurin inhibitor use and can coexist with graft-versus-host disease (GVHD) and radiation nephropathy [<a href="#rid45">45</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1331.html" rel="external">"Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7197.html" rel="external">"Kidney disease following hematopoietic cell transplantation", section on 'Thrombotic microangiopathy'</a>.)</p><p></p><p class="headingAnchor" id="H2136218591"><span class="h3">Nephrotoxic anticancer agents</span><span class="headingEndMark"> — </span>Drug-induced nephrotoxicity is a significant cause of AKI among patients with cancer treated with conventional chemotherapeutic agents, targeted therapies, and immunotherapies  (<a class="graphic graphic_table graphicRef112219" href="/d/graphic/112219.html" rel="external">table 2</a>) [<a href="#rid3">3,46,47</a>]. These drugs can promote kidney injury through a variety of mechanisms that may affect the glomeruli, tubules, interstitium, and/or renal microvasculature [<a href="#rid3">3,46-49</a>]. Importantly, the nephrotoxicity of these agents may be exacerbated by the concurrent or proximate use of other nephrotoxins such as iodinated contrast [<a href="#rid50">50</a>]. As previously noted, drug discontinuation due to nephrotoxicity can limit effective tumor regression and eradication.</p><p>The nephrotoxicity of specific anticancer agents is discussed in more detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2834.html" rel="external">"Nephrotoxicity of chemotherapy and other cytotoxic agents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7231.html" rel="external">"Cisplatin nephrotoxicity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2383.html" rel="external">"Ifosfamide nephrotoxicity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Renal toxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3191.html" rel="external">"Intraperitoneal chemotherapy for treatment of ovarian cancer", section on 'Nephrotoxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2955.html" rel="external">"Treatment-related toxicity in testicular germ cell tumors", section on 'Renal insufficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Kidney'</a>.)</p><p></p><p class="headingAnchor" id="H2008858452"><span class="h3">Less common etiologies</span><span class="headingEndMark"> — </span>Less common causes of intrinsic AKI among patients with cancer include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lysozymuria</strong> – This is a rare disorder that has been observed in patients with acute promyelocytic, monocytic, or chronic myelomonocytic leukemia [<a href="#rid51">51,52</a>]. In these cases, clonal proliferation of mononuclear cells produces large quantities of lysozyme, which is reabsorbed by proximal tubular cells, a process that leads to toxic proximal tubular injury. Elevated serum and urine lysozyme concentrations are suggestive of the diagnosis. Kidney biopsy may show positive staining for lysozyme by immunohistochemistry and accumulation of lysosomes in damaged proximal tubular cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Proliferative/crescentic glomerulonephritis</strong> – Both membranoproliferative and rapidly progressive glomerulonephritis have been described in isolated patients with solid tumors and lymphomas, although the etiologic relationship between these conditions is not proven [<a href="#rid53">53,54</a>]. There is some evidence that malignancy is more frequent in patients diagnosed with ANCA vasculitis compared with the general population or with those who have other forms of vasculitis [<a href="#rid55">55</a>]. A high percentage of patients over the age of 50 years who are diagnosed with C3 glomerulopathy have an underlying monoclonal gammopathy. Thus, monoclonal gammopathies should be excluded as the cause in such patients [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3055.html" rel="external">"Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis", section on 'Monoclonal gammopathies'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/109635.html" rel="external">"Diagnosis and treatment of monoclonal gammopathy of renal significance", section on 'Patients with C3 glomerulopathy with monoclonal gammopathy'</a>.)</p><p></p><p class="headingAnchor" id="H681703622"><span class="h2">Postrenal causes</span><span class="headingEndMark"> — </span>Urinary tract obstruction should be considered as a cause of AKI in patients with cancer, especially those with malignancies of the bladder, prostate, uterus, or cervix. Conversely, malignancy should be considered in any patient not known to have cancer who presents with bilateral urinary tract obstruction that is not associated with kidney stones.</p><p class="headingAnchor" id="H1915898551"><span class="h3">Intratubular obstruction</span><span class="headingEndMark"> — </span>Intratubular obstruction can be caused by crystals composed of uric acid, xanthine, hypoxanthine, or calcium phosphate (in TLS); light chain casts; or crystallization of certain drugs (such as high-dose <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>). Maintaining a high urine output with intravenous fluids in "at-risk" patients is the best way to avoid intratubular precipitation in these settings.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/17050.html" rel="external">"Tumor lysis syndrome: Prevention and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation", section on 'Light chain cast nephropathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7211.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Treatment and prognosis", section on 'Light chain cast nephropathy (myeloma kidney)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7229.html" rel="external">"Crystal-induced acute kidney injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Renal toxicity'</a>.) </p><p></p><p class="headingAnchor" id="H93828895"><span class="h3">Extrarenal obstruction</span><span class="headingEndMark"> — </span>Ureteric obstruction can be caused by a wide range of malignancies (most commonly arising in the gastrointestinal and genitourinary tracts) and usually indicates metastatic disease. The diagnosis is usually established by imaging studies (eg, kidney ultrasound), which typically show dilatation of the collecting system in one or both kidneys (hydronephrosis). Ureteral obstruction due to retroperitoneal tumor or fibrosis (which can be secondary to malignancy) may not be associated with severe hydronephrosis and may require invasive techniques to establish the diagnosis. Patients with cancer may also develop urinary tract obstruction that is unrelated to the malignancy (eg, benign prostatic hyperplasia in men).</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7174.html" rel="external">"Clinical manifestations and diagnosis of urinary tract obstruction (UTO) and hydronephrosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7200.html" rel="external">"Clinical manifestations and diagnosis of retroperitoneal fibrosis", section on 'Diagnostic approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6889.html" rel="external">"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/132696.html" rel="external">"Management of urinary tract obstruction"</a>.) </p><p></p><p>The clinical spectrum of malignant ureteral obstruction was illustrated by a case series of 102 patients [<a href="#rid57">57</a>]. Obstruction was bilateral in 68 percent of patients. Initial management with a percutaneous nephrostomy or ureteral stent was successful in 95 percent of cases. Despite successful decompression, 53 percent of patients developed complications (mostly, urinary tract infection and obstruction of nephrostomy tubes or stents). Overall survival was poor (median of seven months), reflecting the advanced stage of malignancy in such patients.</p><p class="headingAnchor" id="H586192730"><span class="h2">Special AKI populations</span></p><p class="headingAnchor" id="H1537775246"><span class="h3">AKI after hematopoietic cell transplantation</span><span class="headingEndMark"> — </span>Acute kidney injury (AKI) is a common complication after HCT, occurring in 12 to 66 percent of patients [<a href="#rid58">58</a>]. The risk of AKI depends upon the type of HCT performed (allogeneic versus autologous), the conditioning regimen (myeloablative versus nonmyeloablative) used prior to transplantation, as well the use of nephrotoxic medications and development of GVHD. A more detailed discussion of the causes and management of AKI after HCT is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/7197.html" rel="external">"Kidney disease following hematopoietic cell transplantation", section on 'Causes of AKI'</a>.)</p><p class="headingAnchor" id="H2379803052"><span class="h3">AKI after nephrectomy</span><span class="headingEndMark"> — </span>A large percentage of patients with renal cell carcinoma (RCC) have underlying CKD and are at higher risk for postoperative acute kidney injury (AKI) following either radical or partial nephrectomy. Removal of a kidney in such patients is likely to cause AKI because of patients' preexisting kidney disease and diminished kidney functional reserve. Even among patients with an estimated glomerular filtration rate (eGFR) of ≥60 mL/min per 1.73 m<sup>2</sup>, 33 percent develop AKI after a radical nephrectomy, and postoperative AKI is associated with a 4.2-fold increase in the risk of new-onset CKD at one year after surgery [<a href="#rid12">12</a>]. Among patients undergoing partial nephrectomy, nearly 20 percent develop AKI postoperatively [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/d/html/2985.html" rel="external">"Definitive surgical management of renal cell carcinoma"</a>.)</p><p class="headingAnchor" id="H3525038268"><span class="h1">CHRONIC KIDNEY DISEASE IN PATIENTS WITH CANCER</span><span class="headingEndMark"> — </span>Patients with cancer may develop chronic kidney disease (CKD) from causes that are related or unrelated to the malignancy and its treatment. Preexisting CKD among such patients has important implications for issues such as proper drug dosing and avoidance of potential nephrotoxins.</p><p>The management of the complications related to CKD (eg, hypertension, anemia, mineral bone disorder) in patients with cancer is broadly similar to that in patients without cancer and is discussed separately. However, erythropoiesis-stimulating agents should be prescribed with caution because of concerns regarding their adverse effects (including higher rates of thromboembolism and faster progression of the underlying disease) in patients with cancer. (See  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults"</a> and  <a class="medical medical_review" href="/d/html/2799.html" rel="external">"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer"</a>.)</p><p class="headingAnchor" id="H16981134"><span class="h2">Causes of CKD in patients with cancer</span><span class="headingEndMark"> — </span>The causes of chronic kidney disease (CKD) among patients with cancer include all of the causes that are seen in patients without cancer. In addition, kidney insults directly related to cancer or its therapy can lead to progressive CKD [<a href="#rid60">60</a>]. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Prior episodes of acute kidney injury (AKI) (see <a class="local">'Acute kidney injury in patients with cancer'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nephrotoxic anticancer agents (see  <a class="medical medical_review" href="/d/html/2834.html" rel="external">"Nephrotoxicity of chemotherapy and other cytotoxic agents"</a> and  <a class="medical medical_review" href="/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduction in kidney mass following nephrectomy for renal cell (RCC) or urothelial cancers or kidney cancers associated with von Hippel-Lindau disease (see <a class="local">'Patients with renal cell carcinoma'</a> below and  <a class="medical medical_review" href="/d/html/5193.html" rel="external">"Clinical features, diagnosis, and management of von Hippel-Lindau disease"</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic obstructive nephropathy (see  <a class="medical medical_review" href="/d/html/7200.html" rel="external">"Clinical manifestations and diagnosis of retroperitoneal fibrosis"</a> and  <a class="medical medical_review" href="/d/html/7174.html" rel="external">"Clinical manifestations and diagnosis of urinary tract obstruction (UTO) and hydronephrosis"</a> and  <a class="medical medical_review" href="/d/html/102837.html" rel="external">"Chronic kidney disease (newly identified): Clinical presentation and diagnostic approach in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Kidney irradiation</p><p></p><p>A discussion of the causes, clinical manifestations, and evaluation of CKD is presented in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/102837.html" rel="external">"Chronic kidney disease (newly identified): Clinical presentation and diagnostic approach in adults"</a>.)</p><p class="headingAnchor" id="H1203520395"><span class="h2">Special CKD populations</span></p><p class="headingAnchor" id="H15894487"><span class="h3">Patients with renal cell carcinoma</span><span class="headingEndMark"> — </span>Chronic kidney disease (CKD) occurs commonly in patients with RCC, either as a preexisting condition or as a consequence of treatment [<a href="#rid13">13</a>]. Patients who have localized RCC are typically treated with radical or partial nephrectomy depending upon factors such as the size and location of the tumor as well as the baseline kidney function of the patient. However, patients who undergo nephrectomy for RCC are at risk for developing CKD as a consequence of the reduction in kidney mass and other factors, such as the development of postoperative AKI. Observational studies have shown that the risk of CKD is greater with radical nephrectomy than with partial nephrectomy [<a href="#rid61">61-65</a>]. A clinical scoring system based upon readily available parameters has been developed to identify patients at higher risk of developing significant CKD after nephrectomy [<a href="#rid66">66</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2985.html" rel="external">"Definitive surgical management of renal cell carcinoma", section on 'Overview of the surgical approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma", section on 'Localized renal cell carcinoma'</a>.)</p><p></p><p>Among patients who undergo nephrectomy for localized RCC, approximately 25 to 30 percent have preexisting CKD [<a href="#rid61">61,67</a>]. This high prevalence may reflect the presence of risk factors that are common to both RCC and CKD, such as older age, male sex, smoking, obesity, diabetes, and hypertension [<a href="#rid12">12,68-72</a>]. Assessment of the non-neoplastic tissue obtained from tumor nephrectomy specimens may provide important information about the cause of CKD and risk of progression in these patients [<a href="#rid73">73-75</a>]. In one study, for example, medical kidney disease (most frequently, diabetic kidney disease and hypertensive nephropathy) was identified in 15 percent of tumor nephrectomy specimens; 74 percent of these cases also showed evidence of severe arteriolosclerosis [<a href="#rid73">73</a>]. Another study of tumor nephrectomy specimens found that larger glomeruli in the deep cortex and wider distal tubular diameters in the superficial cortex were independent predictors of progressive CKD [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H4276803388"><span class="h1">PROTEINURIA OR NEPHROTIC SYNDROME IN PATIENTS WITH CANCER</span><span class="headingEndMark"> — </span>Patients with cancer may present with proteinuria or the nephrotic syndrome, which can be caused by the underlying malignancy (paraneoplastic) or its treatment. Chemotherapy-associated glomerular diseases may present at various times during treatment, and therefore, patients receiving these drugs (especially therapies targeting the vascular endothelial growth factor [VEGF] pathway as well as immune checkpoint inhibitors) should be monitored for the development of proteinuria and/or kidney function impairment. In addition, proteinuria and the nephrotic syndrome are common presenting features of disorders associated with monoclonal gammopathies. (See  <a class="medical medical_review" href="/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Kidney toxicity'</a>.)</p><p class="headingAnchor" id="H3607447457"><span class="h2">Paraneoplastic glomerular diseases</span><span class="headingEndMark"> — </span>The development of proteinuria and of the nephrotic syndrome has been associated with several malignancies  (<a class="graphic graphic_table graphicRef112217" href="/d/graphic/112217.html" rel="external">table 3</a>). Among the cancer-associated glomerular diseases, membranous nephropathy (MN) and minimal change disease (MCD) are the most common. An association with malignancy has also been described with membranoproliferative glomerulonephritis, immunoglobulin A (IgA) nephropathy [<a href="#rid77">77</a>], IgA vasculitis (Henoch-Schönlein purpura [HSP]) [<a href="#rid78">78</a>], and amyloid A (AA) amyloidosis [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/d/html/3055.html" rel="external">"Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis", section on 'Rare causes'</a>.)</p><p class="headingAnchor" id="H471568076"><span class="h3">Membranous nephropathy</span><span class="headingEndMark"> — </span>MN is the most common glomerular disease in patients with cancer [<a href="#rid80">80,81</a>]. MN may be associated with solid tumors (such as carcinomas of the lung, prostate, or gastrointestinal tract) or, less frequently, with a hematologic malignancy (such as chronic lymphocytic leukemia [CLL]); it may also occur after hematopoietic cell transplantation (HCT). Typically, these patients are more likely to be negative for anti-phospholipase A2 receptor (PLA2R) or thrombospondin type-1 domain-containing 7A (THSD7A) antibodies, which may be a clue to an underlying malignancy. There is a strong association between malignancy and nerve epidermal growth factor-like 1 (NELL1)-associated MN [<a href="#rid82">82</a>]. (See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Malignancy'</a> and  <a class="medical medical_review" href="/d/html/7197.html" rel="external">"Kidney disease following hematopoietic cell transplantation", section on 'Nephrotic syndrome'</a>.)</p><p>Treatment of the cancer is often associated with improvement of the kidney disease. Patients diagnosed with MN of unclear etiology should undergo routine cancer screening. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/117886.html" rel="external">"Membranous nephropathy: Clinical manifestations and diagnosis", section on 'Screening for malignancy'</a>.)</p><p class="headingAnchor" id="H3806097857"><span class="h3">Minimal change disease</span><span class="headingEndMark"> — </span>MCD may occur in association with Hodgkin lymphoma and, less commonly, other lymphoproliferative disorders as well as solid tumors. One putative mechanism is secretion of a glomerular-toxic lymphokine by abnormal T cells. Lymphoma-associated MCD is frequently resistant to treatment with glucocorticoids and <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid83">83,84</a>]; therefore, a poor response to the treatment of MCD with these agents should prompt an investigation for an underlying malignancy. In some but not all patients with lymphoma-associated MCD, the course of MCD correlates with that of the lymphoma. (See  <a class="medical medical_review" href="/d/html/3046.html" rel="external">"Minimal change disease: Etiology, clinical features, and diagnosis in adults", section on 'Malignancies'</a>.)</p><p class="headingAnchor" id="H2590566064"><span class="h2">Chemotherapy-associated glomerular disorders</span><span class="headingEndMark"> — </span>A number of agents used in the treatment of cancer have been associated with the development of proteinuria and/or the nephrotic syndrome. Kidney biopsy is recommended in these cases to determine the associated pathology and to guide therapy. These include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Bisphosphonates – Collapsing focal segmental glomerulosclerosis (FSGS) has been associated with exposure to high doses of intravenous bisphosphonates, particularly <a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">pamidronate</a>, in patients with cancer. Such patients typically present with nephrotic syndrome and kidney failure. Stopping the bisphosphonate may improve kidney function, but most patients have residual kidney disease, and some progress to end-stage kidney disease (ESKD). (See  <a class="medical medical_review" href="/d/html/2806.html" rel="external">"Risks of therapy with bone antiresorptive agents in patients with advanced malignancy", section on 'Proteinuria and kidney injury'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interferons – Chronic therapy with interferon-alpha, -beta, or -gamma has been associated with the development of FSGS not otherwise specified (NOS), collapsing FSGS, and MCD. The onset of proteinuria and/or nephrotic syndrome may occur days to years after the initiation of interferon treatment. Discontinuation of interferon generally leads to complete remission of nephrotic syndrome in patients with MCD; however, remission is less consistent in those with collapsing FSGS or FSGS NOS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mechanistic (previously called mammalian) target of rapamycin (mTOR) inhibitors – <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">Sirolimus</a> has been associated with proteinuria and collapsing FSGS. In addition, rare cases of membranoproliferative glomerulonephritis, MN, and IgA nephropathy have reported in patients treated with sirolimus. (See  <a class="medical medical_review" href="/d/html/7329.html" rel="external">"Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors", section on 'Proteinuria'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immune checkpoint inhibitors – Antibody-induced lupus nephritis has been reported in patients treated with the checkpoint inhibitor, <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Kidney'</a>.)</p><p></p><p class="headingAnchor" id="H2399014959"><span class="h2">Disorders associated with monoclonal gammopathy</span><span class="headingEndMark"> — </span>Proteinuria or nephrotic syndrome can occur in patients who have multiple myeloma or other monoclonal gammopathies. (See  <a class="medical medical_review" href="/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation", section on 'Albuminuria or nephrotic syndrome'</a>.)</p><p class="headingAnchor" id="H1445572304"><span class="h3">Amyloidosis</span><span class="headingEndMark"> — </span>Amyloidosis is a group of diseases characterized by the extracellular deposition of Congo red-positive fibrils in soft tissues. In immunoglobulin (Ig)-associated amyloidosis, the fibrils can consist of monoclonal light chains (AL), heavy chains (AH), or both light and heavy chains (AHL). AL amyloidosis is by far the most common, accounting for more than 94 percent of cases [<a href="#rid86">86</a>]. Patients with Ig-associated amyloidosis typically present with proteinuria and nephrotic syndrome as well as kidney function impairment. (See  <a class="medical medical_review" href="/d/html/3120.html" rel="external">"Renal amyloidosis"</a> and  <a class="medical medical_review" href="/d/html/6668.html" rel="external">"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis"</a>.)</p><p class="headingAnchor" id="H901562798"><span class="h3">Monoclonal immunoglobulin deposition disease</span><span class="headingEndMark"> — </span>Monoclonal immunoglobulin deposition disease (MIDD) is characterized by the deposition of nonamyloid monoclonal light and/or heavy chains within basement membranes. MIDD is pathogenetically similar to Ig-associated amyloidosis except that the light (or heavy) chain fragments do not form fibrils, and the deposits are Congo red negative. Three subtypes of MIDD have been reported based upon the composition of the deposits: light chain deposition disease (LCDD), heavy chain deposition disease (HCDD), and light and heavy chain deposition disease (LHCDD). MIDD is most frequently associated with multiple myeloma but can also occur in patients with Waldenström macroglobulinemia, CLL, and nodal marginal zone lymphoma [<a href="#rid87">87,88</a>]. MIDD typically presents with proteinuria, kidney function impairment, and hypertension.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6665.html" rel="external">"Monoclonal immunoglobulin deposition disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation", section on 'Monoclonal immunoglobulin deposition disease'</a>.)</p><p></p><p class="headingAnchor" id="H4293144884"><span class="h3">Less common causes</span><span class="headingEndMark"> — </span>Other monoclonal gammopathy-associated disorders that can cause proteinuria and nephrotic syndrome include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Monoclonal cryoglobulinemia (see  <a class="medical medical_review" href="/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation", section on 'Less common causes of albuminuria'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Membranoproliferative glomerulonephritis (eg, proliferative glomerulonephritis with monoclonal immunoglobulin deposition [PGNMID], C3 glomerulopathy associated with monoclonal gammopathy)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3055.html" rel="external">"Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis", section on 'Monoclonal gammopathies'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation", section on 'Membranoproliferative glomerulonephritis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Crystalline podocytopathy (see  <a class="medical medical_review" href="/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation", section on 'Less common causes of albuminuria'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibrillary glomerulonephritis and immunotactoid glomerulopathy (see  <a class="medical medical_review" href="/d/html/3115.html" rel="external">"Glomerular diseases due to nonamyloid fibrillar deposits"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Membranous-like nephropathy with masked immunoglobulin G (IgG)-kappa (see  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Membranous-like nephropathy with masked IgG-kappa'</a>)</p><p></p><p class="headingAnchor" id="H2303731545"><span class="h1">ELECTROLYTE DISORDERS IN PATIENTS WITH CANCER</span><span class="headingEndMark"> — </span>Electrolyte disorders are commonly seen in patients with malignancies, and in many cases, the etiologies of these disorders are the same as those seen in the general population. In other circumstances, electrolyte disorders can be caused by the cancer (ie, paraneoplastic syndromes) or its treatment.</p><p class="headingAnchor" id="H2164353090"><span class="h2">Spurious electrolyte disorders</span><span class="headingEndMark"> — </span>Several electrolytes can be erroneously increased or decreased due to various artifactual laboratory abnormalities [<a href="#rid89">89</a>]. This laboratory effect can complicate the interpretation and management of some patients with cancer. Pseudohyponatremia, pseudohypokalemia, pseudohyperkalemia, pseudohypophosphatemia, and pseudohyperphosphatemia are examples of this phenomenon. Recognizing these forms of pseudo–electrolyte disorders is necessary to prevent incorrect and potentially life-threatening interventions.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/115534.html" rel="external">"Causes of hyponatremia without hypotonicity (including pseudohyponatremia)", section on 'Pseudohyponatremia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2341.html" rel="external">"Causes of hypokalemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2377.html" rel="external">"Causes and evaluation of hyperkalemia in adults", section on 'Pseudohyperkalemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/830.html" rel="external">"Hypophosphatemia: Causes of hypophosphatemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/828.html" rel="external">"Overview of the causes and treatment of hyperphosphatemia", section on 'Pseudohyperphosphatemia'</a>.)</p><p></p><p class="headingAnchor" id="H2500455613"><span class="h2">Hyponatremia</span><span class="headingEndMark"> — </span>Hyponatremia is the most common electrolyte disorder encountered in patients with malignancy, occurring in up to 47 percent of hospitalized patients with cancer [<a href="#rid90">90,91</a>]. Hyponatremia in these patients is associated with increased hospital length of stay, increased mortality, and poor response to therapy [<a href="#rid92">92</a>]. The causes of hyponatremia among patients with cancer include all of the causes of hyponatremia among patients without cancer. There are two major mechanisms of hyponatremia in patients with cancer:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypovolemia due to gastrointestinal fluid losses, poor oral intake, and/or effective circulating volume depletion (such as with third-spacing of fluids, heart failure, or cirrhosis). (See  <a class="medical medical_review" href="/d/html/2374.html" rel="external">"Causes of hypotonic hyponatremia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Syndrome of inappropriate antidiuretic hormone (SIADH). SIADH may result from the ectopic production of antidiuretic hormone (ADH) by malignancies such as small-cell cancer of the lung, head and neck tumors, and primary or secondary brain tumors. In addition, SIADH can be induced by high-dose intravenous <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and the vinca alkaloids, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> or <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)", section on 'Malignancies'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/2834.html" rel="external">"Nephrotoxicity of chemotherapy and other cytotoxic agents", section on 'Cyclophosphamide'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/2834.html" rel="external">"Nephrotoxicity of chemotherapy and other cytotoxic agents", section on 'Vinca alkaloids'</a>.)</p><p></p><p>In patients with SIADH, the aggressive hydration administered with certain chemotherapy regimens may worsen hyponatremia, and the serum sodium must be closely monitored. Water restriction can be problematic in patients with cancer, particularly for those with stomatitis or other difficulties in maintaining oral hydration and nutrition, and should be prescribed with caution.</p><p>Rarely, hyponatremia is reported as a side effect of several molecularly targeted chemotherapeutic agents. (See  <a class="medical medical_review" href="/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy"</a>.)</p><p>The evaluation and treatment of hyponatremia are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/2354.html" rel="external">"Diagnostic evaluation of adults with hyponatremia"</a> and  <a class="medical medical_review" href="/d/html/2350.html" rel="external">"Overview of the treatment of hyponatremia in adults"</a>.)</p><p class="headingAnchor" id="H4141827790"><span class="h2">Hypernatremia</span><span class="headingEndMark"> — </span>Arginine vasopressin disorders (previously known as diabetes insipidus), with polyuria and polydipsia, can occur in patients with cancer. Hypernatremia will develop if the patient does not have access to or cannot drink water:</p><p class="bulletIndent1"><span class="glyph">●</span>Primary or secondary malignancies in the brain (most often, lung cancer, leukemia, or lymphoma) can involve the hypothalamic-pituitary region and lead to arginine vasopressin deficiency (AVP-D, previously known as central diabetes insipidus); neurosurgery for brain tumors is also an important cause. (See  <a class="medical medical_review" href="/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypercalcemia in patients with cancer can lead to reversible arginine vasopressin resistance (AVP-R, previously known as nephrogenic diabetes insipidus). (See  <a class="medical medical_review" href="/d/html/842.html" rel="external">"Hypercalcemia of malignancy: Mechanisms"</a> and  <a class="medical medical_review" href="/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"</a>.)</p><p></p><p>Less commonly, ectopic production of adrenocorticotropic hormone (ACTH) by tumor cells (in the setting of severe Cushing's syndrome) can cause hypernatremia [<a href="#rid93">93,94</a>].</p><p>The evaluation and treatment of hypernatremia are discussed separately. (See  <a class="medical medical_review" href="/d/html/2376.html" rel="external">"Etiology and evaluation of hypernatremia in adults"</a> and  <a class="medical medical_review" href="/d/html/2339.html" rel="external">"Treatment of hypernatremia in adults"</a>.)</p><p class="headingAnchor" id="H3770174770"><span class="h2">Hypercalcemia</span><span class="headingEndMark"> — </span>Hypercalcemia is a relatively common complication of malignancy that is most often caused by the release of parathyroid hormone-related peptide (PTHrP) or local osteolysis (mediated by cytokines)  (<a class="graphic graphic_table graphicRef74189" href="/d/graphic/74189.html" rel="external">table 4</a>) [<a href="#rid95">95</a>]. Rarely, hypercalcemia is due to ectopic production of 1,25-dihydroxyvitamin D (calcitriol) in patients with lymphoma. Tumors that secrete PTHrP include squamous cell carcinomas; renal cell carcinoma (RCC); adenocarcinomas of the breast, prostate, and ovary; and certain lymphomas. Local osteolytic mechanisms are seen with multiple myeloma, lymphomas, and breast cancer. (See  <a class="medical medical_review" href="/d/html/842.html" rel="external">"Hypercalcemia of malignancy: Mechanisms"</a>.)</p><p>PTHrP shares the same N-terminal end as parathyroid hormone (PTH) and can bind to the same receptor, the type 1 PTH receptor. As a result, PTHrP can simulate most of the actions of PTH, including increases in bone resorption and distal tubular calcium reabsorption and inhibition of proximal tubular phosphate transport [<a href="#rid96">96</a>].</p><p>Treatment of cancer-associated hypercalcemia centers on aggressive intravenous hydration to increase renal calcium excretion and to treat concomitant volume depletion, followed by therapy with either a bisphosphonate, <a class="drug drug_general" data-topicid="9182" href="/d/drug information/9182.html" rel="external">calcitonin</a>, or <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a> to decrease bone release of calcium [<a href="#rid95">95</a>]. Patients with abnormal kidney function who are receiving denosumab should be monitored closely for hypocalcemia [<a href="#rid97">97</a>]. Glucocorticoids may be used in patients with lymphoma and endogenous overproduction of calcitriol. (See  <a class="medical medical_review" href="/d/html/850.html" rel="external">"Treatment of hypercalcemia"</a>.)</p><p>An abnormal total serum calcium concentration in the presence of a normal ionized calcium concentration (pseudohypercalcemia) can occur in patients with multiple myeloma. (See  <a class="medical medical_review" href="/d/html/845.html" rel="external">"Relation between total and ionized serum calcium concentrations", section on 'Multiple myeloma'</a>.)</p><p class="headingAnchor" id="H747229088"><span class="h2">Hypokalemia</span><span class="headingEndMark"> — </span>Hypokalemia can result from gastrointestinal losses (due to vomiting or diarrhea induced by chemotherapy) or from renal losses (due to <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, or diuretics, or, in some patients with leukemia, associated with lysozymuria) [<a href="#rid98">98,99</a>]. Hypokalemia may also be caused by the paraneoplastic secretion of ectopic adrenocorticotropic hormone (ACTH) in the setting of neuroendocrine tumors, most commonly arising in the lung (bronchial carcinoid tumors), small-cell lung cancer, lung adenocarcinomas, and medullary thyroid tumors [<a href="#rid100">100</a>]. (See  <a class="medical medical_review" href="/d/html/2341.html" rel="external">"Causes of hypokalemia in adults"</a>.)</p><p>Spurious hypokalemia (pseudohypokalemia) may occur in patients with a large number of metabolically active blood cells, such as those with acute myeloid leukemia and a marked leukocytosis. (See  <a class="medical medical_review" href="/d/html/2341.html" rel="external">"Causes of hypokalemia in adults", section on 'Increased blood cell production'</a>.)</p><p class="headingAnchor" id="H4175899177"><span class="h2">Hyperkalemia</span><span class="headingEndMark"> — </span>Hyperkalemia may result from kidney failure of any cause or tumor lysis syndrome (TLS), which is also accompanied by hyperphosphatemia, hypocalcemia, and hyperuricemia. (See  <a class="medical medical_review" href="/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors", section on 'Clinical manifestations'</a>.)</p><p>Of particular importance in this patient population is pseudohyperkalemia, usually in the setting of marked leukocytosis or thrombocytosis [<a href="#rid101">101</a>]. This is due to a shift of potassium out of platelets or leukocytes after a blood draw and when a blood clot has formed. The measurement of a plasma sample, rather than a serum sample, for potassium levels should be considered in the patient with marked thrombocytosis or leukocytosis to avoid this occurrence. (See  <a class="medical medical_review" href="/d/html/2377.html" rel="external">"Causes and evaluation of hyperkalemia in adults", section on 'Pseudohyperkalemia'</a>.)</p><p class="headingAnchor" id="H3554254651"><span class="h2">Hypophosphatemia</span><span class="headingEndMark"> — </span>Hypophosphatemia can occur in patients with cancer who develop proximal tubular dysfunction due to toxic light chains in multiple myeloma. In such patients, hypophosphatemia may be accompanied by other abnormalities including glucosuria, hypouricemia, aminoaciduria, and renal tubular acidosis (Fanconi syndrome). (See  <a class="medical medical_review" href="/d/html/830.html" rel="external">"Hypophosphatemia: Causes of hypophosphatemia", section on 'Fanconi syndrome'</a> and  <a class="medical medical_review" href="/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation", section on 'Light chain proximal tubulopathy'</a>.)</p><p>Hypophosphatemia is also a common side effect of <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>, a molecularly targeted agent that is used for treatment of chronic myelogenous leukemia, and gastrointestinal stromal tumors. (See  <a class="medical medical_review" href="/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy", section on 'Imatinib'</a>.)</p><p>A rare and indolent condition that leads to hypophosphatemia is the syndrome of tumor-induced osteomalacia or oncogenic osteomalacia in which tumor production of phosphaturic factors, such as fibroblast growth factor (FGF)-23, results in renal phosphate wasting and osteomalacia [<a href="#rid102">102</a>]. Most of the malignancies associated with this syndrome are mesenchymal tumors (ie, chondrosarcoma, osteoblastoma, and solitary fibrous tumor/hemangiopericytoma). The mainstay of therapy for this syndrome is tumor resection, although monoclonal antibodies targeting FGF-23 may prove to be an effective alternative. (See  <a class="medical medical_review" href="/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia", section on 'Tumor-induced osteomalacia'</a>.)</p><p class="headingAnchor" id="H1286477129"><span class="h2">Hyperphosphatemia</span><span class="headingEndMark"> — </span>Hyperphosphatemia can occur in patients with TLS and is caused by the release of intracellular phosphate from lysed tumor cells. (See  <a class="medical medical_review" href="/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors", section on 'Hyperphosphatemia'</a> and  <a class="medical medical_review" href="/d/html/828.html" rel="external">"Overview of the causes and treatment of hyperphosphatemia", section on 'Tumor lysis syndrome'</a>.)</p><p>In patients with multiple myeloma and Waldenström macroglobulinemia, circulating monoclonal proteins can interfere with the laboratory measurement of phosphate, resulting in spuriously elevated serum phosphate levels (pseudohyperphosphatemia). (See  <a class="medical medical_review" href="/d/html/828.html" rel="external">"Overview of the causes and treatment of hyperphosphatemia", section on 'Pseudohyperphosphatemia'</a>.)</p><p class="headingAnchor" id="H2797858225"><span class="h2">Hypomagnesemia</span><span class="headingEndMark"> — </span>Tubular dysfunction due to chemotherapy drugs, particularly <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, and the inhibitors of the epidermal growth factor receptor (EGFR) pathway, can lead to urinary magnesium wasting and hypomagnesemia. Particularly with cisplatin, this can persist for years after drug administration.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7231.html" rel="external">"Cisplatin nephrotoxicity", section on 'Hypomagnesemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/829.html" rel="external">"Hypomagnesemia: Causes of hypomagnesemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2955.html" rel="external">"Treatment-related toxicity in testicular germ cell tumors", section on 'Electrolyte disorders'</a>.)</p><p></p><p class="headingAnchor" id="H3113461969"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110749.html" rel="external">"Society guideline links: Chronic kidney disease in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/119821.html" rel="external">"Society guideline links: Cancer of the kidney and ureters"</a>.)</p><p class="headingAnchor" id="H3425282259"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment of kidney function </strong>– Patients with cancer require frequent assessment of kidney function to ensure proper dosing of chemotherapeutic agents and to monitor ongoing therapies for evidence of nephrotoxicity. The assessment of kidney function among patients with cancer is similar to that in patients without cancer. (See <a class="local">'Assessment of kidney function in patients with cancer'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney complications in patients with cancer</strong> – A variety of kidney complications can occur among patients with cancer, including acute kidney injury (AKI), chronic kidney disease (CKD), proteinuria and nephrotic syndrome, and electrolyte disorders. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute kidney injury </strong>– AKI is a common occurrence in patients with cancer. In general, the same etiologies of AKI that occur in the general population can affect patients with cancer; however, certain causes of AKI are specific to this group. AKI in patients with cancer can be divided into prerenal, intrinsic renal, or postrenal causes. (See <a class="local">'Postrenal causes'</a> above and <a class="local">'Acute kidney injury in patients with cancer'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic kidney disease </strong>– Patients with cancer may develop CKD from causes that are related or unrelated to the malignancy and its treatment. Kidney insults directly related to cancer or its therapy include prior episodes of AKI, nephrotoxic anticancer agents, a reduction in kidney mass following nephrectomy for renal cell (RCC) or urothelial cancers, chronic obstructive nephropathy, and kidney irradiation. (See <a class="local">'Chronic kidney disease in patients with cancer'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Proteinuria or nephrotic syndrome </strong>– Patients with cancer may present with proteinuria and the nephrotic syndrome, which can be caused by the underlying malignancy (paraneoplastic) or its treatment. The most common paraneoplastic glomerular diseases are membranous nephropathy (MN) and minimal change disease (MCD). Proteinuria and nephrotic syndrome may be the presenting features of disorders associated with monoclonal gammopathies, including amyloidosis and monoclonal immunoglobulin deposition disease (MIDD). Chemotherapy-associated glomerular diseases may present at various times during treatment, and therefore, patients receiving these drugs should be monitored for the development of proteinuria and/or kidney function impairment. (See <a class="local">'Proteinuria or nephrotic syndrome in patients with cancer'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Electrolyte disorders </strong>– Electrolyte disorders are commonly seen in patients with malignancies, and in many cases, the etiologies of these disorders are the same as those seen in the general population. In other circumstances, electrolyte disorders can be caused by the cancer (ie, paraneoplastic syndromes) or its treatment. Common abnormalities include hyponatremia, hypernatremia, hypercalcemia, hypokalemia, hyperkalemia, hypophosphatemia, hyperphosphatemia, and hypomagnesemia. (See <a class="local">'Electrolyte disorders in patients with cancer'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Hoybert DL, Xu J. Deaths: Preliminary data for 2011. National Vital Statistics Report 2012; 61. http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_06.pdf (Accessed on September 22, 2016).</li><li><a class="nounderline abstract_t">Canet E, Zafrani L, Lambert J, et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One 2013; 8:e55870.</a></li><li><a class="nounderline abstract_t">Rosner MH, Perazella MA. Acute Kidney Injury in Patients with Cancer. N Engl J Med 2017; 376:1770.</a></li><li><a class="nounderline abstract_t">Cheng Y, Nie S, Li L, et al. Epidemiology and outcomes of acute kidney injury in hospitalized cancer patients in China. Int J Cancer 2019; 144:2644.</a></li><li><a class="nounderline abstract_t">Péron J, Neven A, Collette L, et al. Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials. Nephrol Dial Transplant 2020.</a></li><li><a class="nounderline abstract_t">Xiong M, Wang L, Su L, et al. Acute kidney injury among hospitalized children with cancer. Pediatr Nephrol 2021; 36:171.</a></li><li><a class="nounderline abstract_t">Christiansen CF, Johansen MB, Langeberg WJ, et al. Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med 2011; 22:399.</a></li><li><a class="nounderline abstract_t">Kitchlu A, McArthur E, Amir E, et al. Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study. J Natl Cancer Inst 2019; 111:727.</a></li><li><a class="nounderline abstract_t">Libório AB, Abreu KL, Silva GB Jr, et al. Predicting hospital mortality in critically ill cancer patients according to acute kidney injury severity. Oncology 2011; 80:160.</a></li><li><a class="nounderline abstract_t">Darmon M, Ciroldi M, Thiery G, et al. Clinical review: specific aspects of acute renal failure in cancer patients. Crit Care 2006; 10:211.</a></li><li><a class="nounderline abstract_t">Lahoti A, Kantarjian H, Salahudeen AK, et al. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer 2010; 116:4063.</a></li><li><a class="nounderline abstract_t">Cho A, Lee JE, Kwon GY, et al. Post-operative acute kidney injury in patients with renal cell carcinoma is a potent risk factor for new-onset chronic kidney disease after radical nephrectomy. Nephrol Dial Transplant 2011; 26:3496.</a></li><li><a class="nounderline abstract_t">Hu SL, Chang A, Perazella MA, et al. The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma. J Am Soc Nephrol 2016; 27:2227.</a></li><li><a class="nounderline abstract_t">Benoit DD, Hoste EA. Acute kidney injury in critically ill patients with cancer. Crit Care Clin 2010; 26:151.</a></li><li><a class="nounderline abstract_t">Darmon M, Thiery G, Ciroldi M, et al. Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med 2005; 33:2488.</a></li><li><a class="nounderline abstract_t">Soares M, Salluh JI, Carvalho MS, et al. Prognosis of critically ill patients with cancer and acute renal dysfunction. J Clin Oncol 2006; 24:4003.</a></li><li><a class="nounderline abstract_t">Cho S, Kang E, Kim JE, et al. Clinical Significance of Acute Kidney Injury in Lung Cancer Patients. Cancer Res Treat 2021; 53:1015.</a></li><li><a class="nounderline abstract_t">Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110:1376.</a></li><li><a class="nounderline abstract_t">Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol 2010; 30:548.</a></li><li><a class="nounderline abstract_t">Iff S, Craig JC, Turner R, et al. Reduced estimated GFR and cancer mortality. Am J Kidney Dis 2014; 63:23.</a></li><li><a class="nounderline abstract_t">Na SY, Sung JY, Chang JH, et al. Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality. Am J Nephrol 2011; 33:121.</a></li><li><a class="nounderline abstract_t">Königsbrügge O, Lötsch F, Zielinski C, et al. Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. Thromb Res 2014; 134:44.</a></li><li><a class="nounderline abstract_t">Kim CS, Kim B, Suh SH, et al. Risk of Kidney Failure in Patients With Cancer: A South Korean Population-Based Cohort Study. Am J Kidney Dis 2022; 79:507.</a></li><li><a class="nounderline abstract_t">Kooijmans ECM, van der Pal HJH, Pluijm SMF, et al. The Dutch Childhood Cancer Survivor Study (DCCSS)-LATER 2 kidney analysis examined long-term glomerular dysfunction in childhood cancer survivors. Kidney Int 2022; 102:1136.</a></li><li><a class="nounderline abstract_t">Yang Y, Li HY, Zhou Q, et al. Renal Function and All-Cause Mortality Risk Among Cancer Patients. Medicine (Baltimore) 2016; 95:e3728.</a></li><li><a class="nounderline abstract_t">Lowrance WT, Ordoñez J, Udaltsova N, et al. CKD and the risk of incident cancer. J Am Soc Nephrol 2014; 25:2327.</a></li><li><a class="nounderline abstract_t">Stewart JH, Buccianti G, Agodoa L, et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 2003; 14:197.</a></li><li><a class="nounderline abstract_t">Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354:93.</a></li><li><a class="nounderline abstract_t">Mach T, Qi A, Bouganim N, Trinh E. Targeted Cancer Therapies Causing Elevations in Serum Creatinine Through Tubular Secretion Inhibition: A Case Report and Review of the Literature. Can J Kidney Health Dis 2022; 9:20543581221106246.</a></li><li><a class="nounderline abstract_t">Campbell GA, Hu D, Okusa MD. Acute kidney injury in the cancer patient. Adv Chronic Kidney Dis 2014; 21:64.</a></li><li><a class="nounderline abstract_t">Lameire N, Vanholder R, Van Biesen W, Benoit D. Acute kidney injury in critically ill cancer patients: an update. Crit Care 2016; 20:209.</a></li><li><a class="nounderline abstract_t">Lam AQ, Humphreys BD. Onco-nephrology: AKI in the cancer patient. Clin J Am Soc Nephrol 2012; 7:1692.</a></li><li><a class="nounderline abstract_t">Simsek S, Oen AL, Comans EF, et al. Acute renal failure due to non-Hodgkin lymphoma infiltration of the kidneys detected by ultrasonography and confirmed by positron emission tomography. Clin Nephrol 2003; 59:383.</a></li><li><a class="nounderline abstract_t">Lundberg WB, Cadman ED, Finch SC, Capizzi RL. Renal failure secondary to leukemic infiltration of the kidneys. Am J Med 1977; 62:636.</a></li><li><a class="nounderline abstract_t">Kaya Z, Alıcı N, Özmen ÖE, et al. Identification of renal infiltration based on urinary findings in a child with Burkitt leukemia/lymphoma. Am J Hematol 2017; 92:839.</a></li><li><a class="nounderline abstract_t">Lommatzsch SE, Bellizzi AM, Cathro HP, Rosner MH. Acute renal failure caused by renal infiltration by hematolymphoid malignancy. Ann Diagn Pathol 2006; 10:230.</a></li><li><a class="nounderline abstract_t">RICHMOND J, SHERMAN RS, DIAMOND HD, CRAVER LF. Renal lesions associated with malignant lymphomas. Am J Med 1962; 32:184.</a></li><li><a class="nounderline abstract_t">Cohen LJ, Rennke HG, Laubach JP, Humphreys BD. The spectrum of kidney involvement in lymphoma: a case report and review of the literature. Am J Kidney Dis 2010; 56:1191.</a></li><li><a class="nounderline abstract_t">Iványi B. Renal complications in multiple myeloma. Acta Morphol Hung 1989; 37:235.</a></li><li><a class="nounderline abstract_t">Nasr SH, Valeri AM, Sethi S, et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis 2012; 59:786.</a></li><li><a class="nounderline abstract_t">Lohrmann HP, Adam W, Heymer B, Kubanek B. Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases. Ann Intern Med 1973; 79:368.</a></li><li><a class="nounderline abstract_t">Antman KH, Skarin AT, Mayer RJ, et al. Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore) 1979; 58:377.</a></li><li><a class="nounderline abstract_t">Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 2015; 66:857.</a></li><li><a class="nounderline abstract_t">Mazzierli T, Allegretta F, Maffini E, Allinovi M. Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management. Front Pharmacol 2022; 13:1088031.</a></li><li><a class="nounderline abstract_t">Chapin J, Shore T, Forsberg P, et al. Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol 2014; 12:565.</a></li><li><a class="nounderline abstract_t">Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol 2012; 7:1713.</a></li><li><a class="nounderline abstract_t">Lameire N, Kruse V, Rottey S. Nephrotoxicity of anticancer drugs--an underestimated problem? Acta Clin Belg 2011; 66:337.</a></li><li><a class="nounderline abstract_t">Markowitz GS, Bomback AS, Perazella MA. Drug-induced glomerular disease: direct cellular injury. Clin J Am Soc Nephrol 2015; 10:1291.</a></li><li><a class="nounderline abstract_t">Airy M, Raghavan R, Truong LD, Eknoyan G. Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity. Nephrol Dial Transplant 2013; 28:2502.</a></li><li><a class="nounderline abstract_t">Sendur MA, Aksoy S, Yaman S, et al. Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity. J BUON 2013; 18:274.</a></li><li><a class="nounderline abstract_t">Mir MA, Delamore IW. Metabolic disorders in acute myeloid leukaemia. Br J Haematol 1978; 40:79.</a></li><li><a class="nounderline abstract_t">Santoriello D, Andal LM, Cox R, et al. Lysozyme-Induced Nephropathy. Kidney Int Rep 2017; 2:84.</a></li><li><a class="nounderline abstract_t">Alpers CE, Cotran RS. Neoplasia and glomerular injury. Kidney Int 1986; 30:465.</a></li><li><a class="nounderline abstract_t">Birkeland SA, Storm HH. Glomerulonephritis and malignancy: a population-based analysis. Kidney Int 2003; 63:716.</a></li><li><a class="nounderline abstract_t">Pankhurst T, Savage CO, Gordon C, Harper L. Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford) 2004; 43:1532.</a></li><li><a class="nounderline abstract_t">Smith RJH, Appel GB, Blom AM, et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol 2019; 15:129.</a></li><li><a class="nounderline abstract_t">Wong LM, Cleeve LK, Milner AD, Pitman AG. Malignant ureteral obstruction: outcomes after intervention. Have things changed? J Urol 2007; 178:178.</a></li><li><a class="nounderline abstract_t">Kanduri SR, Cheungpasitporn W, Thongprayoon C, et al. Incidence and mortality of acute kidney injury in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. QJM 2020; 113:621.</a></li><li><a class="nounderline abstract_t">Thompson RH, Lane BR, Lohse CM, et al. Renal function after partial nephrectomy: effect of warm ischemia relative to quantity and quality of preserved kidney. Urology 2012; 79:356.</a></li><li><a class="nounderline abstract_t">Wu NL, Chen Y, Dieffenbach BV, et al. Development and Validation of a Prediction Model for Kidney Failure in Long-Term Survivors of Childhood Cancer. J Clin Oncol 2023; 41:2258.</a></li><li><a class="nounderline abstract_t">Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006; 7:735.</a></li><li><a class="nounderline abstract_t">Klarenbach S, Moore RB, Chapman DW, et al. Adverse renal outcomes in subjects undergoing nephrectomy for renal tumors: a population-based analysis. Eur Urol 2011; 59:333.</a></li><li><a class="nounderline abstract_t">Sun M, Bianchi M, Hansen J, et al. Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. Eur Urol 2012; 62:696.</a></li><li><a class="nounderline abstract_t">Leppert JT, Lamberts RW, Thomas IC, et al. Incident CKD after Radical or Partial Nephrectomy. J Am Soc Nephrol 2018; 29:207.</a></li><li><a class="nounderline abstract_t">Streja E, Kalantar-Zadeh K, Molnar MZ, et al. Radical versus partial nephrectomy, chronic kidney disease progression and mortality in US veterans. Nephrol Dial Transplant 2018; 33:95.</a></li><li><a class="nounderline abstract_t">Ellis RJ, Del Vecchio SJ, Gallagher KMJ, et al. A Simple Clinical Tool for Stratifying Risk of Clinically Significant CKD after Nephrectomy: Development and Multinational Validation. J Am Soc Nephrol 2020; 31:1107.</a></li><li><a class="nounderline abstract_t">Mashni JW, Assel M, Maschino A, et al. New Chronic Kidney Disease and Overall Survival After Nephrectomy for Small Renal Cortical Tumors. Urology 2015; 86:1137.</a></li><li><a class="nounderline abstract_t">Malcolm JB, Bagrodia A, Derweesh IH, et al. Comparison of rates and risk factors for developing chronic renal insufficiency, proteinuria and metabolic acidosis after radical or partial nephrectomy. BJU Int 2009; 104:476.</a></li><li><a class="nounderline abstract_t">Stiles KP, Moffatt MJ, Agodoa LY, et al. Renal cell carcinoma as a cause of end-stage renal disease in the United States: patient characteristics and survival. Kidney Int 2003; 64:247.</a></li><li><a class="nounderline abstract_t">Song C, Bang JK, Park HK, Ahn H. Factors influencing renal function reduction after partial nephrectomy. J Urol 2009; 181:48.</a></li><li><a class="nounderline abstract_t">Vaglio A, Buzio L, Cravedi P, et al. Prognostic significance of albuminuria in patients with renal cell cancer. J Urol 2003; 170:1135.</a></li><li><a class="nounderline abstract_t">Tourojman M, Kirmiz S, Boelkins B, et al. Impact of Reduced Glomerular Filtration Rate and Proteinuria on Overall Survival of Patients with Renal Cancer. J Urol 2016; 195:588.</a></li><li><a class="nounderline abstract_t">Salvatore SP, Cha EK, Rosoff JS, Seshan SV. Nonneoplastic renal cortical scarring at tumor nephrectomy predicts decline in kidney function. Arch Pathol Lab Med 2013; 137:531.</a></li><li><a class="nounderline abstract_t">Gautam G, Lifshitz D, Shikanov S, et al. Histopathological predictors of renal function decrease after laparoscopic radical nephrectomy. J Urol 2010; 184:1872.</a></li><li><a class="nounderline abstract_t">Henriksen KJ, Meehan SM, Chang A. Non-neoplastic renal diseases are often unrecognized in adult tumor nephrectomy specimens: a review of 246 cases. Am J Surg Pathol 2007; 31:1703.</a></li><li><a class="nounderline abstract_t">Denic A, Gaddam M, Moustafa A, et al. Tubular and Glomerular Size by Cortex Depth as Predictor of Progressive CKD after Radical Nephrectomy for Tumor. J Am Soc Nephrol 2023; 34:1535.</a></li><li><a class="nounderline abstract_t">Mustonen J, Pasternack A, Helin H. IgA mesangial nephropathy in neoplastic diseases. Contrib Nephrol 1984; 40:283.</a></li><li><a class="nounderline abstract_t">Pertuiset E, Lioté F, Launay-Russ E, et al. Adult Henoch-Schönlein purpura associated with malignancy. Semin Arthritis Rheum 2000; 29:360.</a></li><li><a class="nounderline abstract_t">Vanatta PR, Silva FG, Taylor WE, Costa JC. Renal cell carcinoma and systemic amyloidosis: demonstration of AA protein and review of the literature. Hum Pathol 1983; 14:195.</a></li><li><a class="nounderline abstract_t">Bacchetta J, Juillard L, Cochat P, Droz JP. Paraneoplastic glomerular diseases and malignancies. Crit Rev Oncol Hematol 2009; 70:39.</a></li><li><a class="nounderline abstract_t">Jhaveri KD, Shah HH, Calderon K, et al. Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int 2013; 84:34.</a></li><li><a class="nounderline abstract_t">Caza TN, Hassen SI, Dvanajscak Z, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int 2021; 99:967.</a></li><li><a class="nounderline abstract_t">Audard V, Larousserie F, Grimbert P, et al. Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature. Kidney Int 2006; 69:2251.</a></li><li><a class="nounderline abstract_t">Da'as N, Polliack A, Cohen Y, et al. Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur J Haematol 2001; 67:158.</a></li><li><a class="nounderline abstract_t">Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009; 361:211.</a></li><li><a class="nounderline abstract_t">Said SM, Sethi S, Valeri AM, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol 2013; 8:1515.</a></li><li><a class="nounderline abstract_t">Went P, Ascani S, Strøm E, et al. Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. Lancet Oncol 2004; 5:381.</a></li><li><a class="nounderline abstract_t">Vos JM, Gustine J, Rennke HG, et al. Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol 2016; 175:623.</a></li><li><a class="nounderline abstract_t">Chowdhury R, Turcotte AE, Rondon-Berrios H, Workeneh BT. Spurious Electrolyte and Acid-Base Disorders in the Patient With Cancer: A Review. Am J Kidney Dis 2023; 82:237.</a></li><li><a class="nounderline abstract_t">Doshi SM, Shah P, Lei X, et al. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis 2012; 59:222.</a></li><li><a class="nounderline abstract_t">Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer 2000; 8:192.</a></li><li><a class="nounderline abstract_t">Rosner MH, Dalkin AC. Electrolyte disorders associated with cancer. Adv Chronic Kidney Dis 2014; 21:7.</a></li><li><a class="nounderline abstract_t">Wenk RE, Bhagavan BS, Levy R, et al. Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia. Cancer 1977; 40:773.</a></li><li><a class="nounderline abstract_t">Brzezniak CE, Vietor N, Hogan PE, et al. A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome. Case Rep Oncol 2017; 10:321.</a></li><li><a class="nounderline abstract_t">Rosner MH, Dalkin AC. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol 2012; 7:1722.</a></li><li><a class="nounderline abstract_t">Soki FN, Park SI, McCauley LK. The multifaceted actions of PTHrP in skeletal metastasis. Future Oncol 2012; 8:803.</a></li><li><a class="nounderline abstract_t">Qi WX, Lin F, He AN, et al. Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies. Curr Med Res Opin 2013; 29:1067.</a></li><li><a class="nounderline abstract_t">Schlondorff JS, Mendez GP, Rennke HG, Magee CC. Electrolyte abnormalities and progressive renal failure in a cancer patient. Kidney Int 2007; 71:1181.</a></li><li><a class="nounderline abstract_t">Evans JJ, Bozdech MJ. Hypokalemia in nonblastic chronic myelogenous leukemia. Arch Intern Med 1981; 141:786.</a></li><li><a class="nounderline abstract_t">Torpy DJ, Mullen N, Ilias I, Nieman LK. Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci 2002; 970:134.</a></li><li><a class="nounderline abstract_t">Sevastos N, Theodossiades G, Archimandritis AJ. Pseudohyperkalemia in serum: a new insight into an old phenomenon. Clin Med Res 2008; 6:30.</a></li><li><a class="nounderline abstract_t">Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer 2011; 18:R53.</a></li></ol></div><div id="topicVersionRevision">Topic 7173 Version 49.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_06.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hoybert DL, Xu J. Deaths: Preliminary data for 2011. National Vital Statistics Report 2012; 61. http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_06.pdf (Accessed on September 22, 2016).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23457485" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28467867" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Acute Kidney Injury in Patients with Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30426496" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiology and outcomes of acute kidney injury in hospitalized cancer patients in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32337562" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32712760" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Acute kidney injury among hospitalized children with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21767759" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30423160" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21677465" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Predicting hospital mortality in critically ill cancer patients according to acute kidney injury severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16677413" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical review: specific aspects of acute renal failure in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20564156" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21406544" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Post-operative acute kidney injury in patients with renal cell carcinoma is a potent risk factor for new-onset chronic kidney disease after radical nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26961346" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19944280" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Acute kidney injury in critically ill patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16276171" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16921054" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prognosis of critically ill patients with cancer and acute renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33494125" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical Significance of Acute Kidney Injury in Lung Cancer Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634949" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21146120" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23993153" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Reduced estimated GFR and cancer mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21242672" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24792954" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34416352" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risk of Kidney Failure in Patients With Cancer: A South Korean Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35772499" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The Dutch Childhood Cancer Survivor Study (DCCSS)-LATER 2 kidney analysis examined long-term glomerular dysfunction in childhood cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27196494" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Renal Function and All-Cause Mortality Risk Among Cancer Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24876115" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : CKD and the risk of incident cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12506152" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10408483" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cancer in patients on dialysis for end-stage renal disease: an international collaborative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35756332" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Targeted Cancer Therapies Causing Elevations in Serum Creatinine Through Tubular Secretion Inhibition: A Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24359988" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acute kidney injury in the cancer patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27480256" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acute kidney injury in critically ill cancer patients: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22879433" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Onco-nephrology: AKI in the cancer patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12779102" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Acute renal failure due to non-Hodgkin lymphoma infiltration of the kidneys detected by ultrasonography and confirmed by positron emission tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/265682" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Renal failure secondary to leukemic infiltration of the kidneys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28224662" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Identification of renal infiltration based on urinary findings in a child with Burkitt leukemia/lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16844565" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acute renal failure caused by renal infiltration by hematolymphoid malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14492019" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Renal lesions associated with malignant lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20843590" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The spectrum of kidney involvement in lymphoma: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2486464" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Renal complications in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22417785" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4748253" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/481196" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Microangiopathic hemolytic anemia and cancer: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25943718" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Thrombotic microangiopathy, cancer, and cancer drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36699080" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25654478" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22879440" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Onco-nephrology: renal toxicities of chemotherapeutic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22145268" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Nephrotoxicity of anticancer drugs--an underestimated problem?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25862776" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Drug-induced glomerular disease: direct cellular injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24009289" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23613416" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/280362" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Metabolic disorders in acute myeloid leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29142945" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Lysozyme-Induced Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3537450" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Neoplasia and glomerular injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631139" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Glomerulonephritis and malignancy: a population-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15316126" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Malignancy is increased in ANCA-associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30692664" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : C3 glomerulopathy - understanding a rare complement-driven renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17499300" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Malignant ureteral obstruction: outcomes after intervention. Have things changed?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32101318" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Incidence and mortality of acute kidney injury in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22310752" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Renal function after partial nephrectomy: effect of warm ischemia relative to quantity and quality of preserved kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36795981" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Development and Validation of a Prediction Model for Kidney Failure in Long-Term Survivors of Childhood Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16945768" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21109345" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Adverse renal outcomes in subjects undergoing nephrectomy for renal tumors: a population-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22483407" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29018140" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Incident CKD after Radical or Partial Nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27798198" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Radical versus partial nephrectomy, chronic kidney disease progression and mortality in US veterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32238473" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A Simple Clinical Tool for Stratifying Risk of Clinically Significant CKD after Nephrectomy: Development and Multinational Validation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26362947" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : New Chronic Kidney Disease and Overall Survival After Nephrectomy for Small Renal Cortical Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19220252" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Comparison of rates and risk factors for developing chronic renal insufficiency, proteinuria and metabolic acidosis after radical or partial nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12787416" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Renal cell carcinoma as a cause of end-stage renal disease in the United States: patient characteristics and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19012914" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Factors influencing renal function reduction after partial nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14501709" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Prognostic significance of albuminuria in patients with renal cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26433140" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Impact of Reduced Glomerular Filtration Rate and Proteinuria on Overall Survival of Patients with Renal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23544942" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Nonneoplastic renal cortical scarring at tumor nephrectomy predicts decline in kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20850146" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Histopathological predictors of renal function decrease after laparoscopic radical nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18059227" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Non-neoplastic renal diseases are often unrecognized in adult tumor nephrectomy specimens: a review of 246 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37430426" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Tubular and Glomerular Size by Cortex Depth as Predictor of Progressive CKD after Radical Nephrectomy for Tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6499458" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : IgA mesangial nephropathy in neoplastic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10924021" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Adult Henoch-Schönlein purpura associated with malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6832767" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Renal cell carcinoma and systemic amyloidosis: demonstration of AA protein and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18790651" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Paraneoplastic glomerular diseases and malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23364518" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Glomerular diseases seen with cancer and chemotherapy: a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32828756" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : NELL1 is a target antigen in malignancy-associated membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16672913" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11737248" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemia: a retrospective study in 700 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19587352" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Anti-CTLA4 antibody-induced lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23704299" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15172359" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27468978" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36906215" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Spurious Electrolyte and Acid-Base Disorders in the Patient With Cancer: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22001181" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10789959" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24359982" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Electrolyte disorders associated with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/196743" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28512417" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22879438" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22830401" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The multifaceted actions of PTHrP in skeletal metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23745518" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17332730" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Electrolyte abnormalities and progressive renal failure in a cancer patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6940517" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Hypokalemia in nonblastic chronic myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12381548" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18591376" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pseudohyperkalemia in serum: a new insight into an old phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21490240" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Tumor-induced osteomalacia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
